Dipeptide with xanthine oxidase inhibitory activity and application thereof
By screening out dipeptides with xanthine oxidase inhibitory activity, the problems of hyperuricemia and gout treatment were solved, the effect of reducing uric acid levels and improving kidney damage was achieved, and the intestinal microbiota structure was improved, providing a kind of Safe treatment.
Patent Information
- Application Number
- CN202410889181.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-04
- Publication Date
- 2024-11-01
AI Technical Summary
The prior art is difficult to effectively prevent and treat hyperuricemia and gout, and the drugs have side effects and lack safe and widely used treatment methods.
The Peptide Lego enzymatic software was used to screen dipeptides with xanthine oxidase inhibitory activity, and a peptide library was constructed using human milk protein as raw material. 12 active peptides were screened out, of which 2 dipeptides were stable in simulated digestive fluids. Prepare food or drugs that inhibit xanthine oxidase activity, reduce uric acid levels, and improve renal tissue damage and inflammation caused by hyperuricemia.
Significantly reduce serum uric acid levels, reduce the secretion of proinflammatory factors caused by hyperuricemia, restore the levels of anti-inflammatory factors, improve renal tissue damage, enhance antioxidant properties, slow down the infiltration of inflammatory cells in renal tissue, and improve intestinal microbial structure , improve Firmicutes abundance and downregulate the microbiota associated with hyperuricemia.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioactive peptides, and in particular relates to a dipeptide with xanthine oxidase inhibitory activity and application thereof. Background Art
[0002] With the aging of the population and the increase of unhealthy lifestyles, the morbidity and mortality of chronic diseases such as hypertension, hyperglycemia, hyperuricemia, and cardiovascular disease are increasing. The pathogenesis of chronic diseases is usually complex, involving multiple metabolic pathways, and a large number of related mechanisms have not been fully resolved. Various drugs on the market for the treatment of chronic diseases also have various side effects, and there is a lack of suitable treatments for patients with mild symptoms. For the above reasons, some natural substances with the potential to treat or prevent chronic diseases have attracted the attention of researchers.
[0003] Bioactive peptides are a class of peptide compounds that are beneficial to the life activities of biological organisms or have special biological activities, and their length is generally 2 to 20 amino acids. Food-derived active peptides have the advantages of being natural, low toxicity, and a wide range of sources, and have broad application prospects in the pharmaceutical, health care, food, cosmetics and other industries. Recent studies have widely revealed the function of dietary protein as an important source of bioactive peptides. Bioactive peptides refer to peptides with biological functions or physiological effects produced by enzymatic hydrolysis of dietary proteins in vivo or in vitro. These substances are derived from proteins in bacteria, plants, and animals, especially proteins in milk. They have several beneficial properties, including opioid effects, preventing blood coagulation, lowering blood pressure, regulating the immune system, fighting bacteria, protecting the stomach, and transporting minerals. Bioactive peptides have the ability to be absorbed by the intestines and directly enter the blood. This ensures their presence in the body and allows them to produce physiological effects at the desired location. Based on the amino acid sequence, food-derived peptides can show a wide range of functions, such as opioid, mineral binding, immunomodulatory, antibacterial, antioxidant, antithrombotic, hypercholesterolemic, anticancer, and antihypertensive effects. Net charge, amino acid composition, sequence, length and surface / molecular hydrophobicity all have an impact on the biological activity and function of bioactive peptides. In addition, peptides derived from milk or milk proteins display a wide range of functional capabilities. The use of bioactive peptides derived from dietary proteins offers significant opportunities for integration into functional foods and nutraceuticals.
[0004] Hyperuricemia is a metabolic disease caused by abnormal purine metabolism or uric acid elimination. Its incidence is on the rise worldwide. It is the fourth largest health risk factor after hypertension, hyperglycemia and hyperlipidemia. Long-term hyperuricemia can cause many diseases such as hypertension, cardiovascular disease and kidney disease. When the blood uric acid concentration exceeds the maximum solubility, urate crystals will form, which are easily deposited in tissues such as joints, kidneys, and cartilage, leading to gout.
[0005] Xanthine oxidase (XO) is a key enzyme in the metabolism of purine into uric acid in the human body and is a drug target for gout and hyperuricemia. Therefore, inhibiting XO activity is an effective method for preventing or treating gout and hyperuricemia. Compared with drugs, food-derived bioactive peptides have a wide range of sources and high safety, and have great potential in preventing and treating hyperuricemia. Summary of the invention
[0006] The inventors of this application used Peptide Lego enzymatic hydrolysis software to construct a peptide library using human milk protein as raw material, and used docking binding energy and the interaction between peptide segments and key amino acid residues in the XO active pocket as screening criteria to screen 12 active peptides that have not been reported. These active peptides showed significant in vitro XO inhibitory activity, with IC50 between 9.8 and 18.6 μM, indicating that the high-throughput screening strategy based on docking binding energy and interaction analysis is very effective in screening XO inhibitory peptides. The stability of the 12 highly active XO inhibitory peptides screened in simulated digestive fluid was measured, and the results showed that a total of 2 dipeptides were stable to gastrointestinal digestion. The uric acid-lowering effect of the two dipeptides was further evaluated using a hyperuricemia mouse model induced by potassium oxalate and hypoxanthine, and the results showed that one of the dipeptides could significantly reduce the levels of uric acid, creatinine and urea nitrogen in serum.
[0007] Therefore, the first aspect of the present invention provides a dipeptide having xanthine oxidase inhibitory activity, wherein the amino acid sequence of the dipeptide is NW.
[0008] The second aspect of the present invention provides a gene sequence encoding the dipeptide.
[0009] The third aspect of the present invention provides the use of the dipeptide for preparing food or medicine for inhibiting the activity of xanthine oxidase.
[0010] Furthermore, the inhibition of xanthine oxidase activity includes lowering uric acid.
[0011] Furthermore, the inhibition of xanthine oxidase activity includes reducing the secretion of pro-inflammatory factors caused by hyperuricemia, restoring the levels of anti-inflammatory factors, improving renal tissue damage caused by hyperuricemia, and slowing down the infiltration of inflammatory cells in renal tissue.
[0012] Furthermore, the inhibition of xanthine oxidase activity includes reducing the production of serum uric acid, reducing the production of reactive oxygen species, and alleviating oxidative stress in the body.
[0013] Furthermore, the inhibition of xanthine oxidase activity includes enhancing antioxidant activity and scavenging reactive oxygen species.
[0014] The fourth aspect of the present invention provides another application of the dipeptide for preparing food or medicine for improving and / or repairing the intestinal flora structure.
[0015] Furthermore, the improvement and / or repair of the intestinal flora structure includes increasing the abundance of Firmicutes at the phylum level and downregulating the relative abundance of microorganisms in the intestinal flora that are positively correlated with hyperuricemia.
[0016] Furthermore, the microbial communities in the bacterial flora that are positively correlated with hyperuricemia include Helicobacter and Prevotellaceae.
[0017] The present invention has the following beneficial effects:
[0018] 1. The dipeptide NW with xanthine oxidase inhibitory activity of the present invention can reduce uric acid levels, reduce serum uric acid, restore anti-inflammatory cytokine levels and SCFAs content, scavenge reactive oxygen, enhance antioxidant properties, improve oxidative stress levels and renal tissue damage, and slow down the infiltration of inflammatory cells in renal tissue.
[0019] 2. The dipeptide of the present invention provides a potential effective treatment for hyperuricemia, and provides a strong scientific basis for the application of the dipeptide NW in the field of functional food or medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The inhibitory effect of the peptide at a concentration of 5.0 mg / mL on XO in Example 2, wherein the values represent mean±SD (n=3).
[0021] Figure 2 This is the gastrointestinal stability of dipeptides No. 2 and No. 3 at a concentration of 5.0 mg / mL in Example 3.
[0022] Figure 3 The gastrointestinal stability of dipeptides No. 2 and No. 3 at a concentration of 1.0 mg / mL in Example 3
[0023] Figure 4 This is the animal experiment process of the anti-hyperuricemia effect of high and low doses of dipeptides No. 2 and No. 3 in Example 4.
[0024] Figure 5 These are (a) uric acid levels, (b) creatinine levels, and (c) urine protein levels of the mice in Example 4 after taking allopurinol, high-dose and low-dose dipeptides No. 2 and No. 3 for 4 weeks.
[0025] Figure 6 These are histopathological examination images of mouse kidney tissue after administration of low and high doses of dipeptide No. 3 NW in Example 4 for 4 weeks.
[0026] Figure 7 The inflammatory cytokine levels in the kidneys of mice after administration of high and low doses of dipeptide No. 3 NW for 4 weeks in Example 4, wherein: (a) is IL-10; (b) is IL-1β; (c) is TNF-α; and (d) is IL-6.
[0027] Figure 8 The oxidative stress levels in serum of mice after 4 weeks of administration of high and low doses of dipeptide 3 NW in Example 4. Including: (a) serum MDA level; (b) serum SOD level; (c) serum GSH level.
[0028] Fig. 9 The XO activity in the liver of mice was measured after the mice were given low and high doses of dipeptide No. 3 NW for 4 weeks in Example 4.
[0029] Fig.10 The fecal SCFAs content of the mice in Example 4 after taking low and high doses of dipeptide No. 3 NW for 4 weeks.
[0030] Fig.11 The results of evaluating the β-diversity of the intestinal microbiota of each group of mice by PCoA analysis are shown.
[0031] Fig.12 The relative abundance of intestinal flora in mice of each experimental group is shown.
[0032] Fig.13 Shown are the results of analyzing the abundance levels of Helicobacter at the genus level and Prevotellaceae at the family level. DETAILED DESCRIPTION
[0033] The present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0034] The clean-grade 6-week-old male ICR mice used in the following examples were purchased from Shanghai Jiesijie Experimental Animal Co., Ltd.
[0035] The reagents, instruments and equipment used in the following examples, unless otherwise specified, can be obtained through conventional commercial channels.
[0036] The methods used in the following examples, unless otherwise specified, are all conventional operations in the art, or are performed according to product instructions.
[0037] In the following examples, data analysis was performed using SPSS 27.0 software. Results are presented as mean ± standard deviation (SD). Statistical methods included one-way analysis of variance (ANOVA) using GraphPad Prism 10.0 software to assess differences between different groups. Differences were considered statistically significant if the P value was less than 0.05.
[0038] Example 1. High-throughput screening of XO inhibitory peptides
[0039] The inventors obtained a total of 12 human milk protein amino acid sequences from the uniport database for subsequent virtual hydrolysis and peptide library construction. Peptide Lego software was further used to virtually hydrolyze the 12 human milk protein sequences obtained to obtain a peptide library containing 8844 peptides. The three-dimensional structure of the peptides in the peptide library was obtained using Discovery Studio Client software (DS4.0), and the crystal structure of the complex of XO and the inhibitor quercetin (PDB ID: 3NVY) was obtained from the RCSB protein database. Autodock 4.2 (Vina version) was used for molecular docking. A docking grid frame covering the entire binding pocket including the active site was created to ensure the simulation of molecular docking. The size of the grid frame is 30×30×30, the coordinates are x:37.94, y:13.56, z:20.83, and the grid spacing is The docking process was repeated 50 times. After the calculation was completed, 12 active peptides (numbered 1 to 12) that had not been reported were screened based on the peptides with low ΔG (binding energy) and binding linkage with the active pocket amino acid residues.
[0040] Example 2, XO inhibitory activity assay
[0041] The 12 active peptides screened out were handed over to Shanghai Jiepeptide Biotechnology Co., Ltd. for synthesis, and the obtained active peptides were tested for in vitro XO inhibitory activity.
[0042] XO was prepared in 20mM PBS (pH 7.4) to a concentration of 0.05U / mL. The substrate (xanthine) was first dissolved with 1MNaOH and then prepared in 20mM PBS (pH 7.4) to a concentration of 0.5mM. The reaction was performed on a 96-well UV detection plate. The measurement was divided into four groups: control group A, control group B, sample group A, and sample group B. After the reaction was completed, 25μL HCl (0.5M) was added to terminate the reaction, and the OD of the solution after the reaction was measured using a microplate reader. 290 All samples were run in triplicate, and the reaction system is shown in Table 1.
[0043] Table 1: Reaction system for XO inhibitory activity assay
[0044]
[0045] The XO inhibitory activity of the 12 samples was calculated according to the following formula: iA is the OD of sample group A 290 , A iB is the OD of sample group B 290 , A cA is the OD of control group A 290 , A cB is the OD of control group B 290 .
[0046]
[0047] Figure 1 The XO activity inhibition rates of the 12 dipeptides at a concentration of 5.0 mg / mL are shown. Among the 12 dipeptides, the inhibition rates of dipeptides No. 4, No. 9, and No. 10 are relatively high, at 84.5%, 78.1%, and 76.8%, respectively. The activity inhibition rate of dipeptide No. 12 is the lowest, at 39.9%.
[0048] Table 2 lists the dipeptides with inhibitory effects and their corresponding IC50 values.
[0049] Table 2: XO inhibitory activity of human milk protein derived dipeptides
[0050]
[0051] comprehensive Figure 1 As shown in the results of Table 2, after in vitro activity assay, the IC50 values of these inhibitory peptides were between 9.8 and 18.6 μM, among which peptide No. 10 had the highest inhibitory activity.
[0052] Example 3. Evaluation of gastrointestinal stability of inhibitory peptides.
[0053] The 12 inhibitory peptides obtained were dissolved in 0.1M KCl-HCl buffer at pH 2.0 to concentrations of 1.0mg / mL and 5.0mg / mL, respectively. Pepsin with an enzyme activity of 503U / mg was added to the solution until the final concentration reached 0.4mg / mL. The resulting mixture was incubated at 37°C for 4h to accelerate the digestion process. The mixture was then boiled for 15min to stop the digestion process, and the pH of the mixture was adjusted to 7.0 with 1.0M NaOH solution. After neutralization, the mixture was centrifuged at 12000rpm for 5min, and 1.0mL of the liquid was taken after centrifugation for the inhibition of XO. The remaining solution was further digested with trypsin at 37°C for 4h, and the residual liquid was evaluated to determine its XO inhibitory properties.
[0054] In vitro experimental results showed that only two inhibitory peptides, No. 2 and No. 3, could maintain their potent XO inhibitory activity after exposure to simulated gastrointestinal fluid and digestive enzymes.
[0055] like Figure 2 and Figure 3 As shown, the incubation process of dipeptides No. 2 and No. 3 with simulated gastric fluid at concentrations of 5.0 mg / mL and 1.0 mg / mL respectively is shown. In the figure, GC is the peptide sample and simulated gastric fluid without pepsin; G is the dipeptide sample containing gastric fluid and pepsin; G+IC is the dipeptide sample containing gastric fluid and intestinal fluid but without pepsin and trypsin; G+I is the dipeptide sample in gastric fluid and intestinal fluid containing pepsin and trypsin. After being tested under four different conditions, Figure 2 and Figure 3 The results showed that there was no significant change in the activity inhibition rate of dipeptides 2 and 3, and their gastrointestinal stability was good.
[0056] Example 4: Experimental Animal Grouping and Treatment
[0057] The mice were kept at a temperature of 24±2°C, and the environment was kept in a 12-hour light and 12-hour dark cycle, and the mice had unrestricted access to food and water. After a week of environmental adaptation, the mice were randomly assigned to seven groups, with eight mice in each group. These groups were named: normal control group (Normal), model group (Model), allopurinol positive group (Allopurinol), high-dose group of dipeptide No. 3 (3#High), high-dose group of dipeptide No. 2 (2#High), low-dose group of dipeptide No. 3 (3#Low), and low-dose group of dipeptide No. 2 (2#Low).
[0058] Experimental design and dosage Figure 4 As shown, the experimental time was 6 weeks. During this period, except for the normal control group, the other six groups were intragastrically administered 300 mg / kg of potassium oxalate and hypoxanthine every day. CMC-Na solution was used as a suspension for the hyperuricemia model. Both dipeptides No. 2 and No. 3 have significant XO inhibitory activity, so the dose of the high-dose group of dipeptides No. 2 and No. 3 was 10 mg per kilogram of body weight of the mouse. The dose of the low-dose group of dipeptides No. 2 and No. 3 was 2 mg / kg per kilogram of body weight of the mouse. Two weeks after modeling, each group of mice was treated with drugs, and the dosing samples of each group were dissolved in normal saline. The normal group and the model group were intragastrically injected with the same dose of normal saline.
[0059] On the last two days of the experiment, fresh feces of mice in each group were collected and stored in a -80°C refrigerator. The mice were fasted for 12 hours before dissection, and then the final modeling and processing were performed. Blood was collected 1 hour after modeling, and then the mice were slaughtered and dissected. The whole blood of the mice was kept at 4°C for 2 hours, and then centrifuged at 3000rpm for 10 minutes. The serum was divided into small portions and stored in a -80°C refrigerator.
[0060] Example 5: Effects of dipeptide on three items of renal function in mice
[0061] The concentrations of uric acid, blood urea nitrogen and creatinine in the serum of each group of mice in Example 4 were detected using a fluorescence detection kit. Figure 5 The uric acid, blood urea nitrogen and creatinine levels of mice in each group after taking allopurinol, high-dose and low-dose peptide 2 and 3 dipeptide for 4 weeks. Among them, (a) is the uric acid level, (b) is the creatinine level, and (c) is the urine protein level.
[0062] like Figure 5 As shown in the figure, after 2 weeks of intragastric injection of hypoxanthine and potassium oxalate at 300 mg / kg each, the serum uric acid level of the model group mice increased by 52% compared with the normal group mice (p<0.05), indicating that the hyperuricemia mouse model was successfully established. Furthermore, Figure 5 The results showed that both low-dose and high-dose dipeptide 3 could effectively reduce blood uric acid levels, especially high-dose dipeptide 3, which significantly reduced blood uric acid levels compared with other treatment groups (p<0.01) and effectively restored uric acid levels to a near normal range, indicating that high-dose dipeptide 3 has a good ability to reduce uric acid in vivo. However, compared with the model group mice, the serum uric acid levels of the dipeptide 2 mice in the low-dose and high-dose groups did not decrease significantly.
[0063] Serum creatinine and urea nitrogen are two indicators for evaluating renal function. Creatinine is a product of muscle metabolism, while urea nitrogen is an indicator for evaluating glomerular filtration function. Excessive uric acid concentration in serum will increase the burden on the kidneys and easily lead to kidney disease. Figure 5It can be seen that compared with the normal group of mice, as the uric acid level of the model group mice increased, the serum creatinine and urea nitrogen levels also increased (significant p<0.001 and p<0.001, respectively). Compared with dipeptide 2, dipeptide 3 can continuously reduce blood urea nitrogen and serum creatinine levels regardless of the dosage. High doses of dipeptide 3 have a significant therapeutic effect on blood urea nitrogen and serum creatinine levels. All three indicators have effectively returned to normal levels, and there is no statistically significant difference compared with the levels of normal group mice. The creatinine and urea nitrogen levels of mice in the allopurinol group increased significantly, indicating that although allopurinol can reduce the uric acid level in mice, it also has a significant toxic effect on the animal kidneys. After evaluation, the performance of dipeptide 2 in reducing serum uric acid levels, serum creatinine and urea nitrogen levels was not statistically significant, so only dipeptide 3 was selected for further evaluation, and the sequence of dipeptide 3 is NW.
[0064] Low and high doses of dipeptide 2 had no significant effect on reducing the levels of uric acid, creatinine and urea nitrogen in the blood. However, low and high doses of dipeptide 3 could significantly reduce the levels of uric acid, creatinine and urea nitrogen in the serum, almost restoring them to the levels of the normal mouse group, indicating that dipeptide 3 (NW) can reduce uric acid and alleviate the damage to the kidneys of hyperuricemia.
[0065] Example 6. Histopathological analysis of mouse kidney.
[0066] The mouse kidneys of Example 4 were fixed with 4% paraformaldehyde and then sliced in cooperation with Wuhan Saiwei Biotechnology Co., Ltd. The kidney tissue was prepared into hematoxylin-eosin (HE staining method) slices according to the pathological detection SOP. After the final specimens passed the microscopic examination, CaseViewer 2.2 was used to browse the digital slices, observe the kidney tissue structure in detail at 200 times and 400 times, and analyze typical pathological changes such as inflammation, necrosis, degeneration, hyperplasia and fibrosis.
[0067] Figure 6 The results of histopathological sections of the kidneys of mice in each group are shown. The cortex and medulla of the renal tissue of mice in the normal group were clearly demarcated, the glomerular morphology and structure were normal, the renal tubules were closely arranged, and there was no obvious inflammatory cell infiltration. The renal tissue volume of mice in the allopurinol group was reduced, and the renal tubules were completely damaged. The kidneys of mice in the model group showed interstitial inflammation, accompanied by a small amount of interstitial connective tissue hyperplasia (black arrow) and local tubular necrosis (red arrow), as well as more tubular dilatation (green arrow), inflammatory cell foci, and a small amount of epithelial cell shedding (yellow arrow).
[0068] Damage and tubular dilatation lead to massive connective tissue hyperplasia and inflammatory cell infiltration in the renal interstitium. Compared with the model group, renal tissue damage in the low-dose and high-dose NW groups was significantly improved, with clear boundaries between the cortex and medulla, clear glomerular capillary loop structures, no obvious abnormalities in morphology and structure, and only a few renal tubules dilated. Although allopurinol treatment can reduce uric acid levels in hyperuricemic mice, it can cause severe renal damage.
[0069] Renal tissue pathological analysis showed that the model group mice showed special pathological changes, such as glomerular atrophy, tubular dilatation, and brush border cell shedding, which were significantly improved after treatment with low-dose and high-dose NW. This shows that both low-dose and high-dose dipeptide NW have a protective effect on the kidneys, can significantly improve kidney damage caused by hyperuricemia, and slow down the infiltration of inflammatory cells in kidney tissue.
[0070] Example 7: Effect of NW on inflammatory cytokines in mouse kidney
[0071] Take an appropriate amount of mouse kidney tissue of Example 4, add RIPA lysis buffer of 9 times the weight of mouse kidney tissue, grind with a high-speed tissue grinder at 4°C, then centrifuge the supernatant, and measure the protein concentration of the supernatant with a BCA protein concentration detection kit. The contents of TNF-α, IL-1β, IL-6 and IL-10 in mouse kidney tissue were detected using corresponding ELISA kits.
[0072] Figure 7 The expression levels of various pro-inflammatory factors in the kidneys of mice 2 weeks after modeling are shown.
[0073] like Figure 7 As shown, 2 weeks after modeling, the levels of pro-inflammatory factors (TNF-α, IL-1β, IL-6) in the kidneys of mice in the model group were significantly increased compared with those in the normal group. On the contrary, the level of anti-inflammatory factor IL-10 decreased significantly. These data indicate that modeling induces a significant inflammatory response in the kidneys of mice. After intragastric injection of allopurinol to mice in the allopurinol-positive group for four consecutive weeks, the levels of the four cytokines in the mice dropped sharply and were significantly lower than those in the normal group.
[0074] Compared with the model group mice, the TNF-α levels of the low-dose and high-dose NW groups were significantly decreased (p<0.001). The IL-10 level of the high-dose NW group mice was higher than that of the model group mice, but there was no significant difference in the IL-10 level of the low-dose NW group mice compared with the model group mice, while the high-dose NW group mice recovered the anti-inflammatory level close to that of the normal group mice. The TNF-α, IL-6 and IL-1β levels of the high-dose NW group mice were significantly lower than those of the model group mice (the significance levels were p<0.01, p<0.05 and p<0.001, respectively), and the IL-10 level was significantly higher than that of the model group mice. There was no significant difference in the levels of the four cytokines between the high-dose NW group mice and the normal group mice.
[0075] Figure 7 The data showed that both low-dose and high-dose NW could significantly reduce the secretion of pro-inflammatory factors caused by hyperuricemia and restore the level of anti-inflammatory cytokine IL-10. The measurement results of inflammatory factors were consistent with the results of renal pathological analysis, indicating that dipeptide NW could reduce renal inflammation and renal damage caused by hyperuricemia, among which the effect of high-dose NW was more significant.
[0076] Example 8. Measurement of oxidative stress levels in mice
[0077] The total glutathione (GSH) detection kit and the total SOD activity detection kit were used to determine the GSH content and SOD activity in mouse serum, respectively, and the malondialdehyde (MDA) concentration was determined using the MDA detection kit.
[0078] Figure 8 The oxidative stress levels in serum of mice after 4 weeks of administration of high and low doses of peptide NW in Example 4. Including: (a) serum MDA level; (b) serum SOD level; (c) serum GSH level.
[0079] like Figure 8 As shown in the figure, the serum MDA level of mice in the model group was significantly higher than that in the normal group. Both low and high doses of dipeptide NW helped to reduce the serum MDA level, especially high doses of dipeptide NW could significantly reduce the serum MDA level (p<0.001), which showed that dipeptide NW had strong antioxidant capacity and free radical scavenging properties. Both low and high doses of dipeptide NW could restore the serum MDA level to normal, even lower than the level of the normal group (p<0.05), indicating that it can stimulate or enhance the body's natural antioxidant defense mechanism.
[0080] The results of serum SOD showed that there was no statistical difference between the allopurinol group and the model group, while the effect of low-dose peptide NW was better than that of the positive drug allopurinol, but there was no statistical difference with the model group. High-dose NW can significantly increase serum SOD levels (p<0.001), which shows that NW has strong antioxidant properties and can effectively remove ROS.
[0081] Analysis of serum glutathione (GSH) levels showed no statistically significant difference between the allopurinol group and the normal control group. This result proves that NW supplementation can enhance the body's natural antioxidant defense system and reduce oxidative stress and its harmful effects at the tested dose.
[0082] Low and high doses of dipeptide NW can significantly increase the levels of GSH and SOD, restore serum GSH and SOD activities to normal levels and reduce the level of MDA, thereby significantly improving the oxidative stress level of hyperuricemia mice.
[0083] Example 9: Inhibitory effect of NW on XO activity in mouse liver
[0084] Take an appropriate amount of mouse liver tissue of Example 4, add 9 times the weight of mouse liver tissue with physiological saline, grind with a high-speed tissue grinder at 4°C, and then centrifuge at 12000 rpm to obtain a supernatant. The protein concentration of each shaken supernatant is determined using a BCA protein concentration determination kit, and then the XO activity of the supernatant is determined using an XO activity detection kit.
[0085] XO is a key enzyme in the production of uric acid, and the liver is the main organ expressing XO. Fig. 9 As shown. During the animal culture process, intragastric injection of hypoxanthine into mice led to a large accumulation of uric acid precursors in the mice, resulting in significantly higher XO activity in the liver of the model group mice than in the normal group mice (p<0.001). Allopurinol is an XO inhibitor, so the liver XO activity of the allopurinol group mice was lower than that of the normal group mice.
[0086] Furthermore, by Fig. 9 It can be seen that low-dose and high-dose peptide NW can significantly reduce the XO activity in mouse liver, indicating that low-dose and high-dose NW have a strong inhibitory and regulatory effect on XO activity.
[0087] Example 10: Determination of short-chain fatty acids in mouse feces
[0088] The detection method of SCFA in mouse feces is as follows:
[0089] Take out the mouse feces of Example 4 from the refrigerator, and transfer 50 mg of feces to a 2 ml grinding tube. Add 1 zircon bead with a diameter of 4 mm and 2 zircon grinding beads with a diameter of 3 mm to the grinding tube, and add 500 μL of liquid grade methanol. Use a tissue grinder for grinding, the parameters are 4°C, 60 Hz, grind for 45 seconds, pause for 15 seconds, and then grind for another 45 seconds. After grinding, the grinding liquid sample is ultrasonically treated for 10 minutes, and then centrifuged at 4°C and 12000 rpm for 10 minutes to obtain a supernatant, and the supernatant is centrifuged again with the same parameters to obtain a supernatant without precipitation. After filtering the supernatant without precipitation with a 0.22 μm filter membrane, take 100 μL of the sample and place it in a liquid phase bottle, seal it and measure SCFA. The standard products are acetic acid, propionic acid and butyric acid, with concentrations of 0.05, 0.1, 0.25, 0.5, 1, 10, 25 and 50 μM, respectively. Table 3 lists the HPLC conditions for the detection of SCFA.
[0090] Table 3: HPLC determination conditions of SCFA
[0091]
[0092] The results are as follows Fig.10 As shown in the figure, three common SCFAs in the intestine, including acetate, propionate, and butyrate, were determined by high-performance liquid chromatography. Compared with the feces of mice in the normal group, the concentrations of the three SCFAs in the feces of mice in the model group were significantly reduced. Under the action of high-dose dipeptide NW, the contents of these three SCFAs increased significantly and returned to normal levels. Compared with the feces of mice in the model group, the propionate and butyrate contents of the feces of mice in the low-dose and high-dose NW groups were much higher. The SCFA content in the feces of mice in the allopurinol group did not change significantly compared with the model group. In addition to renal excretion, about 30% of uric acid in the human body is excreted through the intestine, and SCFA has an important regulatory effect on the excretion of uric acid in the intestine. SCFA can serve as an energy source for intestinal epithelial cells, enabling them to release uric acid. SCFAs such as acetate and butyrate can hinder the function of XO in the human body, thereby reducing the production of uric acid. In addition, SCFA has a significant impact on the immune system and inflammatory response.
[0093] The above results indicate that the reduction of SCFA levels is closely related to hyperuricemia. Low-dose and high-dose NW treatment can restore the level of intestinal SCFA in hyperuricemia mice, and has a relieving effect on reducing uric acid and improving inflammation caused by hyperuricemia.
[0094] Example 11: Determination of intestinal flora in mouse feces
[0095] The method for detecting intestinal flora in mouse feces is as follows: take out the mouse feces of Example 4 from the refrigerator, extract DNA using a DNA extraction kit, and detect the purity and concentration of DNA using 1% agarose gel electrophoresis. PCR amplification was performed using 16SV4 region primers (515F and 806R), and the PCR product was detected by electrophoresis using 2% agarose gel, and then magnetic bead purification and enzyme label quantification were performed. 2% agarose gel electrophoresis was used to detect the PCR product, and the target band was recovered using a DNA purification recovery kit. The library was constructed using a library preparation kit, and then the library was quantified and detected. NovaSeq6000 was used for PE 250 on-machine sequencing. FLASH (Version 1.2.11) was used to splice the sequencing results, and fastp software (Version 0.23.1) was used for filtering. The chimeric sequences were compared, detected, and finally removed using the Silva 138.1 database. The Uparse algorithm (Uparse v7.0.1001) was used for clustering, and the sequences were clustered into operational taxonomic units (OTUs) with 97% consistency. The sequences with the highest frequency in OTUs were selected as representative sequences of OTUs. The species classification annotation was performed using the Mothur algorithm based on the Silva 138.1 database. For the top 35 species in each classification level, the pheatmap package of R software (Version 4.0.3) was used to draw a species abundance heat map. β-diversity analysis was performed based on weighted and unweighted distances, and PCoA analysis was performed using R software (Version 4.0.3).
[0096] PCoA analysis was used to evaluate the β-diversity of the intestinal flora of each group of mice. Fig.11 As shown. Compared with the normal group of mice, there is a certain degree of separation between the model group and the normal group, and under the action of low-dose and high-dose dipeptide NW, the spatial distance between the colonies of these two groups and the colonies of the normal group is reduced, indicating that the supplementation of NW can improve and restore the normal colony structure.
[0097] Through species annotation, it was found that Bacteroidota, Firmicutes, Campylobacterota, Actinobacteriota, Pastescibacteria and Desulfobacteota are the six main species types of intestinal flora at the phylum level. Fig.12The relative abundance of intestinal flora of mice in each experimental group is shown. It can be seen that compared with the normal group mice, the relative abundance of Firmicutes in the intestinal flora of the model group mice decreased. After administration of low-dose and high-dose NW, the abundance of Firmicutes returned to the level of the normal group. Firmicutes contains a variety of microorganisms that are beneficial to host health, some of which can directly produce butyrate, which is consistent with the increase in butyrate levels in fecal short-chain fatty acids. Similarly, studies have shown that direct administration of butyrate to the rectum can effectively improve uric acid metabolism in the body.
[0098] The abundance levels of Helicobacter at the genus level and Prevotellaceae at the family level were analyzed. Fig.13 As shown. It can be seen that compared with the normal group of mice, the relative abundance of Helicobacter and Prevotellaceae in the model group mice increased significantly, while after oral administration of low and high doses of dipeptide NW, the relative abundance of Helicobacter and Prevotellaceae decreased significantly. The infection of some Helicobacters is correlated with immunodeficiency, colitis, etc. Helicobacter pylori is a typical pathogenic bacterium among Helicobacters. Clinical studies have shown that the enrichment of H. pylori in the intestine is significantly correlated with the increase in blood uric acid levels. Prevotellaceae has a certain correlation with some metabolic diseases. The abundance of Prevotellaceae in the feces of obese patients is significantly higher than that of normal people. The increase of Prevotellaceae in the intestine is related to intestinal inflammation and sepsis.
[0099] The above results indicate that in addition to directly interacting with the target, dipeptide NW can also regulate the β-diversity of the intestinal flora, restore the normal community structure, increase the abundance of Firmicutes at the phylum level, and downregulate the relative abundance of microbial communities such as Helicobacter and Prevotellaceae in the intestinal flora that are positively correlated with hyperuricemia, thereby further exerting its uric acid-lowering effect.
[0100] It should be noted that the above-described embodiments should be understood as illustrative rather than limiting the scope of protection of the present invention, and the scope of protection of the present invention shall be subject to the claims. For those skilled in the art, without departing from the essence and scope of the present invention, any changes, modifications, substitutions, combinations, and simplifications made shall be equivalent replacement methods and shall be included in the scope of protection of the present invention.
Claims
1. A dipeptide having xanthine oxidase inhibitory activity, characterized in that: The amino acid sequence of the dipeptide is NW.
2. A gene sequence encoding the dipeptide according to claim 1.
3. The use of the dipeptide according to claim 1, characterized in that: Used for preparing food or medicine for inhibiting xanthine oxidase activity.
4. The use according to claim 3, characterized in that: The inhibition of xanthine oxidase activity includes lowering uric acid.
5. The use according to claim 4, characterized in that: The inhibition of xanthine oxidase activity includes reducing the secretion of pro-inflammatory factors caused by hyperuricemia, restoring the level of anti-inflammatory factors, improving renal tissue damage caused by hyperuricemia, and slowing down the infiltration of inflammatory cells in renal tissue.
6. The use according to claim 3, characterized in that: The inhibition of xanthine oxidase activity includes reducing the generation of serum uric acid, reducing the generation of reactive oxygen species, and alleviating oxidative stress in the body.
7. The use according to claim 3, characterized in that: The inhibition of xanthine oxidase activity includes enhancing antioxidant activity and scavenging active oxygen.
8. The use of the dipeptide according to claim 1, characterized in that: Used for preparing food or medicine to improve and / or repair the intestinal flora structure.
9. The use according to claim 8, characterized in that: The improving and / or repairing of the intestinal flora structure includes increasing the abundance of Firmicutes at the phylum level and downregulating the relative abundance of microorganisms in the intestinal flora that are positively correlated with hyperuricemia.
10. The use according to claim 9, characterized in that: The microorganisms in the tract flora that are positively correlated with hyperuricemia include Helicobacter and Prevotellaceae.
